Viewing Study NCT02130193


Ignite Creation Date: 2025-12-25 @ 1:17 AM
Ignite Modification Date: 2026-02-17 @ 6:47 PM
Study NCT ID: NCT02130193
Status: COMPLETED
Last Update Posted: 2017-07-02
First Post: 2013-12-19
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
Sponsor: GlaxoSmithKline
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Pulmonary Disease, Chronic Obstructive View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Efficacy View
None Danirixin View
None EXACT-PRO View
None COPD View
None Safety View
None RD View
None CXCR2 inhibitor View
None EXACT-RS View
None PK View
None HCRU exacerbations View
None PD View